Waheed Jamal

13.6k total citations · 3 hit papers
21 papers, 2.4k citations indexed

About

Waheed Jamal is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Waheed Jamal has authored 21 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Endocrinology, Diabetes and Metabolism, 12 papers in Surgery and 12 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Waheed Jamal's work include Diabetes Treatment and Management (17 papers), Heart Failure Treatment and Management (9 papers) and Pancreatic function and diabetes (9 papers). Waheed Jamal is often cited by papers focused on Diabetes Treatment and Management (17 papers), Heart Failure Treatment and Management (9 papers) and Pancreatic function and diabetes (9 papers). Waheed Jamal collaborates with scholars based in United States, Germany and United Kingdom. Waheed Jamal's co-authors include Martina Brueckmann, Gerasimos Filippatos, Milton Packer, Faı̈ez Zannad, Javed Butler, Stefan D. Anker, Stuart Pocock, João Pedro Ferreira, Anne Pernille Ofstad and Egon Pfarr and has published in prestigious journals such as The Lancet, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Waheed Jamal

17 papers receiving 2.3k citations

Hit Papers

SGLT2 inhibitors in patients with heart failure with redu... 2020 2026 2022 2024 2020 2020 2020 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
    2020 831 citations Faı̈ez Zannad, João Pedro Ferreira et al. The Lancet profile →
  2. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
    2020 266 citations Milton Packer, Stefan D. Anker et al. Circulation profile →
  3. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
    2020 243 citations Stefan D. Anker, Javed Butler et al. Circulation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Waheed Jamal United States 15 1.6k 1.4k 632 523 497 21 2.4k
Jenifer M. Brown United States 23 1.4k 0.9× 830 0.6× 993 1.6× 269 0.5× 190 0.4× 67 2.3k
Robin Mukherjee United States 11 879 0.6× 1.2k 0.9× 1.0k 1.6× 172 0.3× 314 0.6× 16 2.1k
Remo H.M. Furtado Brazil 12 2.5k 1.6× 951 0.7× 1.0k 1.6× 1.0k 2.0× 389 0.8× 30 3.2k
Kreton Mavromatis United States 21 493 0.3× 1.3k 0.9× 877 1.4× 386 0.7× 398 0.8× 58 2.2k
Frans Van de Werf Belgium 8 1.9k 1.2× 611 0.4× 666 1.1× 733 1.4× 91 0.2× 16 2.3k
Annunziata Nusca Italy 18 295 0.2× 1.1k 0.8× 954 1.5× 161 0.3× 194 0.4× 102 2.0k
Stefano Bonapace Italy 26 705 0.5× 1.2k 0.9× 290 0.5× 237 0.5× 195 0.4× 80 2.3k
Arihiro Kiyosue Japan 19 507 0.3× 274 0.2× 486 0.8× 377 0.7× 164 0.3× 72 1.2k
Mark Donovan United States 14 722 0.5× 1.4k 1.0× 226 0.4× 305 0.6× 164 0.3× 21 2.1k
Jinqing Yuan China 18 213 0.1× 954 0.7× 681 1.1× 133 0.3× 160 0.3× 177 1.4k

Countries citing papers authored by Waheed Jamal

Since Specialization
Citations

This map shows the geographic impact of Waheed Jamal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Waheed Jamal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Waheed Jamal more than expected).

Fields of papers citing papers by Waheed Jamal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Waheed Jamal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Waheed Jamal. The network helps show where Waheed Jamal may publish in the future.

Co-authorship network of co-authors of Waheed Jamal

This figure shows the co-authorship network connecting the top 25 collaborators of Waheed Jamal. A scholar is included among the top collaborators of Waheed Jamal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Waheed Jamal. Waheed Jamal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Packer, Milton, Stefan D. Anker, Javed Butler, et al.. (2021). Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload. Journal of the American College of Cardiology. 77(11). 1381–1392. 107 indexed citations
3.
Packer, Milton, James L. Januzzi, João Pedro Ferreira, et al.. (2021). Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR ‐Reduced trial. European Journal of Heart Failure. 23(9). 1529–1538. 28 indexed citations
4.
Ferreira, João Pedro, Faı̈ez Zannad, Stuart Pocock, et al.. (2021). Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure. Journal of the American College of Cardiology. 77(11). 1397–1407. 113 indexed citations
5.
Böhm, Michael, Stefan D. Anker, Javed Butler, et al.. (2021). Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. Journal of the American College of Cardiology. 78(13). 1337–1348. 55 indexed citations
6.
Zannad, Faı̈ez, Javed Butler, Stuart Pocock, et al.. (2021). Cardiovascular and Kidney Outcomes with Empagliflozin in Heart Failure. Diabetologie und Stoffwechsel.
7.
Anker, Stefan D., Javed Butler, Gerasimos Filippatos, et al.. (2020). Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. Circulation. 143(4). 337–349. 243 indexed citations breakdown →
8.
Packer, Milton, Javed Butler, Gerasimos Filippatos, et al.. (2020). Design of a Prospective Patient-Level Pooled Analysis of Two Parallel Trials of Empagliflozin in Patients with Established Heart Failure. European Journal of Heart Failure. 22(12). 2393–2398. 18 indexed citations
9.
Butler, Javed, Stefan D. Anker, Gerasimos Filippatos, et al.. (2020). Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal. 42(13). 1203–1212. 110 indexed citations
10.
Zannad, Faı̈ez, João Pedro Ferreira, Stuart Pocock, et al.. (2020). SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. The Lancet. 396(10254). 819–829. 831 indexed citations breakdown →
11.
McGuire, Darren K., Bernard Zinman, Silvio E. Inzucchi, et al.. (2020). Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. The Lancet Diabetes & Endocrinology. 8(12). 949–959. 50 indexed citations
12.
Packer, Milton, Stefan D. Anker, Javed Butler, et al.. (2020). Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. Circulation. 143(4). 326–336. 266 indexed citations breakdown →
13.
Packer, Milton, Stefan D. Anker, Javed Butler, et al.. (2020). Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal. 42(6). 671–680. 81 indexed citations
14.
Inzucchi, Silvio E., Bernard Zinman, Christoph Wanner, et al.. (2020). 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. Diabetes. 69(Supplement_1). 1 indexed citations
15.
16.
Abraham, William T., Piotr Ponikowski, Martina Brueckmann, et al.. (2019). Rationale and Design of The Emperial-Preserved and Emperial-Reduced Trials of Empagliflozin in Patients with Chronic Heart Failure. European Journal of Heart Failure. 21(7). 932–942. 38 indexed citations
17.
McGuire, Darren K., Bernard Zinman, Silvio E. Inzucchi, et al.. (2019). P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease. European Heart Journal. 40(Supplement_1).
18.
Haas, Sylvia, Reinhold Kreutz, LG Mantovani, et al.. (2013). A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. Thrombosis and Haemostasis. 111(1). 94–102. 71 indexed citations
19.
Kakkar, Ajay K., Iris Mueller, Jean‐Pierre Bassand, et al.. (2011). International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). American Heart Journal. 163(1). 13–19.e1. 171 indexed citations
20.
Meng, Qinghai, Waheed Jamal, Stephen L. Hart, & Jean R. McEwan. (2006). Application to Vascular Adventitia of a Nonviral Vector for TIMP-1 Gene Therapy to Prevent Intimal Hyperplasia. Human Gene Therapy. 0(0). 1527707853–1527707853. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jenifer M. Brown Breakdown of academic impact, for papers by Robin Mukherjee Breakdown of academic impact, for papers by Remo H.M. Furtado Breakdown of academic impact, for papers by Kreton Mavromatis Breakdown of academic impact, for papers by Frans Van de Werf Breakdown of academic impact, for papers by Annunziata Nusca Breakdown of academic impact, for papers by Stefano Bonapace Breakdown of academic impact, for papers by Arihiro Kiyosue Breakdown of academic impact, for papers by Mark Donovan Breakdown of academic impact, for papers by Jinqing Yuan
Rankless by CCL
2026